Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma

Clinical Epigenetics

Table 1 Correlations of PD-L2 methylation with mRNA expression, lymphocyte score, and overall survival

	Methylation or mRNA expression	Correlation with mRNA expression^†		Correlation with lymphocyte score^†		Overall survival (Cox proportional hazards)
Analyte	Mean (95% confidence interval)	Spearman’s ρ	P value	Spearman’s ρ	P value	Hazard ratio (95% CI)	P value
PD-L2 mRNA	94 (79–108)	NA	NA	0.49	< 0.001	0.85 (0.77–0.94)	0.001
cg14440664	72.0 (70.6–73.5)	0.11	0.018	0.10	0.078	0.63 (0.44–0.90)	0.012
cg07211259	25.6 (23.6–27.5)	− 0.43	< 0.001	− 0.22	< 0.001	1.16 (1.02–1.33)	0.027
cg14351952	80.0 (78.8–81.1)	0.23	< 0.001	− 0.02	0.78	0.58 (0.36–0.92)	0.021
cg14133064	51.8 (50.1–53.5)	− 0.18	< 0.001	− 0.27	< 0.001	0.84 (0.63–1.12)	0.24
cg14374994	86.6 (85.9–87.3)	0.32	< 0.001	0.05	0.40	0.30 (0.10–0.86)	0.025

PD-L2 methylation was determined at five different CpG sites each gene targeted by HumanMethylation450 BeadChip beads (Fig. 1). PD-L2 methylation and mRNA expression were analyzed as log2-transformed variable. Significant features are shown in boldface.
^†Correlations were performed including N = 468 (PD-L2 methylation and mRNA expression), N = 328 (lymphocyte score and PD-L2 mRNA expression), N = 329 (lymphocyte score and PD-L2 methylation) samples.

ISSN: 1868-7083